This text is for informational purposes only. Please consult your doctor or pharmacist before using any medication.

Some side effects have been reported, such as:

• Vaginal yeast infections. Women can develop a vaginal odor, white or yellowish vaginal discharge, or vaginal itching.
• Yeast infection of the skin around the penis (balanitis)
• Nasopharyngitis
• Urinary tract infections

If these do not clear up after a few days or worsen, consult with a physician or pharmacist.

Please take time to read the manufacturer’s Product Insert that comes with the medication. Not all side effects are listed here. Consult a healthcare provider if you experience these or other unexpected effects.

Jardiance (empagliflozin) is classified as a sodium glucose cotransporter 2 (SGLT2) inhibitor. These drugs work by preventing the kidneys from releasing glucose into the bloodstream thereby aiding in the elimination of sugars through urine. This mechanism helps in reducing blood sugar levels in individuals with health conditions including:

Type 2 Diabetes

Jardiance is primarily used to manage blood sugar levels in adults with type 2 diabetes mellitus along with a diet and regular exercise routine. By lowering blood glucose levels Jardiance helps reduce the risk of complications associated with diabetes. Studies have demonstrated that Jardiance effectively improves control and offers benefits such as weight loss and lowering blood pressure, which are valuable for comprehensive management of type 2 diabetes.

Heart Failure

Recent research has broadened the scope of Jardiances usage to include treating forms of heart failure not limited to individuals with diabetes. Heart failure with reduced ejection fraction (HFrEF) occurs when the heart muscle fails to contract leading to a decrease in the hearts ability to pump blood efficiently.

In terms of benefits research has indicated that Jardiance can lower the risk of death and hospitalization for heart failure among adults with HFrEF.

Chronic Kidney Disease (CKD)

Athough Jardiance was not initially approved for treating CKD studies have shown that it and other SGLT2 inhibitors hold promise in slowing down CKD progression in individuals with type 2 diabetes. This potential benefit is attributed to the drug’s ability to lower blood glucose levels and its effects on kidney function potentially safeguarding against kidney function decline over time.